Department of Medicine and Respiratory, First Clinical Medical College of Three Gorges University, Yi Chang Central People's Hospital, Institute of Respiratory Diseases, Three Gorges University, Xiling, Yichang, Hubei, China.
J Med Virol. 2020 Nov;92(11):2551-2555. doi: 10.1002/jmv.26052. Epub 2020 Aug 25.
The use of corticosteroids has been controversial in viral pneumonia. In most cases, application of methylprednisolone in severe and critical viral pneumonia patients can quickly alleviate the symptoms of dyspnea and prevent disease progression. However, some scholars have confirmed that corticosteroids delayed the body's clearance of the virus. In our retrospective non-randomized study, 34 patients under 50 years old and diagnosed with coronavirus disease 2019 (COVID-19) were included. According to the given methylprednisolone treatment (n = 18) or not (n = 16), they were separated into two groups. By comparing the clinical data we concluded that corticosteroids therapy can effectively release COVID-19 symptoms such as persistent fever and difficult in breathing, improve oxygenation, and prevent disease progression. However, it can prolong the negative conversion of nucleic acids.
皮质类固醇在病毒性肺炎中的应用一直存在争议。在大多数情况下,应用甲基强的松龙治疗重症和危重症病毒性肺炎患者能迅速缓解呼吸困难症状,并防止病情进展。然而,一些学者已经证实皮质类固醇会延迟机体清除病毒。在我们的回顾性非随机研究中,纳入了 34 名年龄小于 50 岁且被诊断为 2019 冠状病毒病(COVID-19)的患者。根据是否给予甲基强的松龙治疗(n=18),将他们分为两组。通过比较临床数据,我们得出结论:皮质类固醇治疗能有效缓解 COVID-19 症状,如持续发热和呼吸困难,改善氧合,并防止疾病进展。然而,它会延长核酸转阴时间。